NEW YORK, April 06, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of AmTrust Financial Services, Inc. securities (NASDAQ:AFSI) from May 10, 2016 through February 24, 2017, both dates inclusive (the “Class Period”) of the important May 1, 2017 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for AmTrust investors under the federal securities laws.
To join the AmTrust class action, go to http://www.rosenlegal.com/cases-1061.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) AmTrust had ineffective assessment of the risks associated with the financial reporting; (2) AmTrust had an insufficient complement of corporate accounting and corporate financial reporting resources within the organization; (3) in turn, AmTrust lacked effective controls over financial reporting; and (4) as a result, defendants’ statements about AmTrust’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. On February 27, 2017, AmTrust issued a press release revealing that it had identified material weaknesses in its internal control over financial reporting that existed as of December 31, 2016. On this news, shares of AmTrust fell $5.32 per share or over 19% to close at $22.34 per share on February 27, 2017, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 1, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1061.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Attorney Advertising. Prior results do not guarantee a similar outcome.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 



